PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: MARKET SEGMENTATION BY TYPE Market segmentation by type Comparison by type Second-generation ALK inhibitors - Market size and forecast 2018-2023 First-generation ALK inhibitors - Market size and forecast 2018-2023 Third-generation ALK inhibitors - Market size and forecast 2018-2023 Market opportunity by type PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES Market drivers Market challenges PART 11: MARKET TRENDS PART 12: VENDOR LANDSCAPE Overview Landscape disruption Competitive scenario PART 13: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors F. Hoffmann-La Roche Ltd. Novartis AG Pfizer Inc. Takeda Pharmaceutical Co. Ltd. PART 14: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Global pharmaceuticals market Exhibit 02: Segments of global pharmaceuticals market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2018 Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 08: Global market: Year-over-year growth 2019-2023 (%) Exhibit 09: Five forces analysis 2018 Exhibit 10: Five forces analysis 2023 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2018 Exhibit 17: Type - Market share 2018-2023 (%) Exhibit 18: Comparison by type Exhibit 19: Second-generation ALK inhibitors - Market size and forecast 2018-2023 ($ millions) Exhibit 20: Second-generation ALK inhibitors - Year-over-year growth 2019-2023 (%) Exhibit 21: Second-generation ALK inhibitors pipeline Exhibit 22: First-generation ALK inhibitors - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Upcoming patent expiry of XALKORI Exhibit 24: First-generation ALK inhibitors - Year-over-year growth 2019-2023 (%) Exhibit 25: Third-generation ALK inhibitors - Market size and forecast 2018-2023 ($ millions) Exhibit 26: Lorlatinib pipeline Exhibit 27: Third-generation ALK inhibitors - Year-over-year growth 2019-2023 (%) Exhibit 28: Market opportunity by type Exhibit 29: Customer landscape Exhibit 30: Market share by geography 2018-2023 (%) Exhibit 31: Geographic comparison Exhibit 32: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 33: North America - Year-over-year growth 2019-2023 (%) Exhibit 34: Top 3 countries in North America Exhibit 35: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 36: Europe - Year-over-year growth 2019-2023 (%) Exhibit 37: Top 3 countries in Europe Exhibit 38: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 39: Asia - Year-over-year growth 2019-2023 (%) Exhibit 40: Top 3 countries in Asia Exhibit 41: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 42: ROW - Year-over-year growth 2019-2023 (%) Exhibit 43: Top 3 countries in ROW Exhibit 44: Key leading countries Exhibit 45: Market opportunity Exhibit 46: Patient assistance programs Exhibit 47: Alternative therapies for oncology conditions Exhibit 48: Side effects of ALK inhibitors Exhibit 49: Impact of drivers and challenges Exhibit 50: Drugs with respect to their expanded indications Exhibit 51: Vendor landscape Exhibit 52: Landscape disruption Exhibit 53: Vendors covered Exhibit 54: Vendor classification Exhibit 55: Market positioning of vendors Exhibit 56: F. Hoffmann-La Roche Ltd. - Vendor overview Exhibit 57: F. Hoffmann-La Roche Ltd. - Business segments Exhibit 58: F. Hoffmann-La Roche Ltd. - Organizational developments Exhibit 59: F. Hoffmann-La Roche Ltd. - Geographic focus Exhibit 60: F. Hoffmann-La Roche Ltd. - Segment focus Exhibit 61: F. Hoffmann-La Roche Ltd. - Key offerings Exhibit 62: F. Hoffmann-La Roche Ltd. - Key customers Exhibit 63: Novartis AG - Vendor overview Exhibit 64: Novartis AG - Business segments Exhibit 65: Novartis AG - Organizational developments Exhibit 66: Novartis AG - Geographic focus Exhibit 67: Novartis AG - Segment focus Exhibit 68: Novartis AG - Key offerings Exhibit 69: Novartis AG - Key customers Exhibit 70: Pfizer Inc. - Vendor overview Exhibit 71: Pfizer Inc. - Business segments Exhibit 72: Pfizer Inc. - Organizational developments Exhibit 73: Pfizer Inc. - Geographic focus Exhibit 74: Pfizer Inc. - Segment focus Exhibit 75: Pfizer Inc. - Key offerings Exhibit 76: Pfizer Inc. - Key customers Exhibit 77: Takeda Pharmaceutical Co. Ltd. - Vendor overview Exhibit 78: Takeda Pharmaceutical Co. Ltd. - Business segments Exhibit 79: Takeda Pharmaceutical Co. Ltd. - Organizational developments Exhibit 80: Takeda Pharmaceutical Co. Ltd. - Geographic focus Exhibit 81: Takeda Pharmaceutical Co. Ltd. - Key offerings Exhibit 82: Takeda Pharmaceutical Co. Ltd. - Key customers Exhibit 83: Validation techniques employed for market sizing Exhibit 84: Definition of market positioning of vendors

F. Hoffmann-La Roche Ltd. Novartis AG Pfizer Inc. Takeda Pharmaceutical Co. Ltd.